The publication of this infographic was sponsored by Menarini Stemline and is based on a symposium presented at the European Society for Medical Oncology (ESMO) Congress 2024.
This infographic, the second in a three-part series, explores the prevalence of ESR1 mutations in patients with ER+/HER2- advanced breast cancer, as well as frequency of testing for ESR1 mutations in the metastatic setting; liquid biopsy as testing methodology; and ASCO, NCCN, and ESMO guidelines related to ESR1 mutations.
For further data, view the first infographic in this series, ‘Unmet Needs in Second-Line Therapy for ER-Positive, HER2-Negative Advanced Breast Cancer’.
